No Deal: Omnibus Spending Bill Moves Without Part D Discount Relief
Executive Summary
Biopharma lobbying to include provision to reduce the 70% discount on brands in the budget bill runs out of time, leaving industry evaluating other possible legislative vehicles.
You may also be interested in...
Part D Coverage Gap Discount Relief Misses Ride On Opioids Bill
Biopharma will continue to seek ways to pass legislation reducing the 70% discount in Medicare Part D coverage gap but it looks like industry's next chance will be after the November elections.
Pricing Positives From Trump Plan Include Potential 340B Changes, Value-Based Contracts
Industry should be encouraged by Blueprint's interest in examining impact of Medicaid rebates, the annual excise tax, and the 340B program. Document also confirms Administration’s interest in value-based contracting.
Point-Of-Sale Rebates In Part D Could Save Seniors $20bn, PhRMA Argues
PhRMA President Ubl discusses drug pricing advocacy priorities in Medicare Part D during media briefing.